Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2848721rdf:typepubmed:Citationlld:pubmed
pubmed-article:2848721lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:2848721lifeskim:mentionsumls-concept:C2239176lld:lifeskim
pubmed-article:2848721lifeskim:mentionsumls-concept:C2717940lld:lifeskim
pubmed-article:2848721lifeskim:mentionsumls-concept:C0017968lld:lifeskim
pubmed-article:2848721lifeskim:mentionsumls-concept:C0079189lld:lifeskim
pubmed-article:2848721lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:2848721lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:2848721pubmed:issue1-2lld:pubmed
pubmed-article:2848721pubmed:dateCreated1989-1-25lld:pubmed
pubmed-article:2848721pubmed:abstractTextThe regulation of the synthesis of alpha-2-HS glycoprotein (AHSG) by inflammatory mediators from activated monocytes was studied on the human hepatoma cell line HepG2 and compared to that of albumin. Monocyte-conditioned medium, recombinant human interleukin-6 (rhIL6) and interleukin-1 beta (rhIL1 beta) all down-regulated the synthesis of AHSG. This decrease was found both at the protein and the mRNA level. The most efficient mediator was the monocyte-conditioned medium, when rhIL1 beta was found to be less efficient than rhIL6. The combination of rhIL6 and rhIL1 beta resulted in an additive down-regulation of the AHSG mRNA levels. Similar results were obtained with albumin. These data indicate that AHSG is a negative acute-phase protein whose synthesis is regulated by cytokines in a manner similar to that of albumin.lld:pubmed
pubmed-article:2848721pubmed:languageenglld:pubmed
pubmed-article:2848721pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:citationSubsetIMlld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2848721pubmed:statusMEDLINElld:pubmed
pubmed-article:2848721pubmed:monthDeclld:pubmed
pubmed-article:2848721pubmed:issn0014-5793lld:pubmed
pubmed-article:2848721pubmed:authorpubmed-author:ArnaudPPlld:pubmed
pubmed-article:2848721pubmed:authorpubmed-author:LebretonJ PJPlld:pubmed
pubmed-article:2848721pubmed:authorpubmed-author:HironMMlld:pubmed
pubmed-article:2848721pubmed:authorpubmed-author:DaveauMMlld:pubmed
pubmed-article:2848721pubmed:authorpubmed-author:JulesKKlld:pubmed
pubmed-article:2848721pubmed:authorpubmed-author:Christian-Dav...lld:pubmed
pubmed-article:2848721pubmed:issnTypePrintlld:pubmed
pubmed-article:2848721pubmed:day5lld:pubmed
pubmed-article:2848721pubmed:volume241lld:pubmed
pubmed-article:2848721pubmed:ownerNLMlld:pubmed
pubmed-article:2848721pubmed:authorsCompleteYlld:pubmed
pubmed-article:2848721pubmed:pagination191-4lld:pubmed
pubmed-article:2848721pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:meshHeadingpubmed-meshheading:2848721-...lld:pubmed
pubmed-article:2848721pubmed:year1988lld:pubmed
pubmed-article:2848721pubmed:articleTitleThe synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells.lld:pubmed
pubmed-article:2848721pubmed:affiliationINSERM Unité 78, Bois-Guillaume, France.lld:pubmed
pubmed-article:2848721pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:2848721lld:pubmed